Perspective Therapeutics, Inc., a radiopharmaceutical development company specializing in advanced systemic treatments for cancers, has announced its operational highlights and financial results for the third quarter ended September 30, 2026. Chief Executive Officer Thijs Spoor noted that the company has presented clinical data demonstrating the potential of delivering alpha radiation via its proprietary targeted oncology platform.
The company highlighted progress across several clinical programs. For its bamzireotide navoxetan (VMT-α-NET) candidate targeting SSTR2-positive neuroendocrine tumors (NETs) and meningioma, updated interim data were presented at the European Society for Medical Oncology Congress 2026 and the North American Neuroendocrine Tumors Society Multidisciplinary NET Medical Symposium. Enrollment in Cohort 4 of the dose-finding study concluded on October 30, 2026, with 20 patients enrolled. The meningioma cohort remains open with two patients treated as of October 30, 2026. Perspective Therapeutics is targeting an end-of-Phase 2 meeting with the U.S. Food and Drug Administration in the first quarter of 2027, following the grant of European orphan medicinal product designation for gastroenteropancreatic NETs in July 2026.
In its lapemelanotide zapixetar (VMT01) program for MC1R-positive melanoma, longer follow-up data were shared at the Society for Immunotherapy of Cancer 41st Annual Meeting. As of October 30, 2026, 12 patients had been treated in a monotherapy cohort permitting up to a cumulative 9 mCi administered in three treatments of 3.0 mCi every eight weeks. Five patients have been treated since the cohort reopened in the third quarter of 2026, with follow-ups of at least 24 weeks expected by mid-2027.
Regarding PSV359 in fibroblast activation protein alpha-positive solid tumors, the dose-finding study progressed into the third dose cohort during the second quarter of 2026, with 17 patients treated across three cohorts as of September 30, 2026. The FDA granted PSV359 Fast Track Designation in October 2026 for adult patients with locally advanced unresectable and/or metastatic solitary fibrous tumors. Furthermore, Perspective Therapeutics entered into a clinical trial collaboration and supply agreement in September 2026 with Merck to evaluate PSV359 in combination with Keytruda for specific lung and colorectal cancers. Construction at the Chicago metro manufacturing site is expected to conclude in early 2027.
Financial results for the third quarter of 2026 indicated cash, cash equivalents, and short-term investments of approximately $202 million as of September 30, 2026, compared to approximately $145 million as of December 31, 2025. Management expects these funds to support planned clinical milestones and operational investments into 2028. Research and development expenses were $26.1 million for the three months ended September 30, 2026, compared to $20.3 million for the same period in 2025. General and administrative expenses reached $8.3 million compared to $7.7 million in the prior-year period. Net loss for the third quarter of 2026 was $32.4 million, or $0.27 per basic and diluted share, compared to a net loss of $26.0 million, or $0.35 per basic and diluted share, for the third quarter of 2025.
